FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

_			

OMB APPROVAL									
OMB Number:	3235-0287								
Estimated average b	urden								
hours per response:	0.5								

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person* Wassil Jim					2. Issuer Name and Ticker or Trading Symbol Vaxcyte, Inc. [PCVX]								(Check	all appli Directo	,		10% Ov	wner		
	KCYTE, ÎN	C.	(Middle)			3. Date of Earliest Transaction (Month/Day/Year) 09/19/2022								X Officer (give title Other (specify below) Chief Operating Officer						
825 INDUSTRIAL ROAD, STE. 300					4. I	4. If Amendment, Date of Original Filed (Month/Day/Year)								6. Individual or Joint/Group Filing (Check Applicable						
(Street) SAN CA	RLOS CA	A 9	94070		_									Line) X	Form filed by One Reporting Person Form filed by More than One Reporting Person					
(City)	(S	tate) ((Zip)												1 01301	'				
	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																			
Date			2. Transac Date (Month/Da		Execution Date,		ution Date,		3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 a		and 5) Securit Benefic Owned		es ially Following	Form (D) o	n: Direct r Indirect nstr. 4)	7. Nature of Indirect Beneficial Ownership		
								Code	v	Amount	(A) or (D)	Price			action(s) 3 and 4)			(Instr. 4)		
Common Stock			09/19/2	2022	022			M		2,800	A	\$2.	42	45	5,144		D			
Common Stock 09.			09/19/2	2022	022			S ⁽¹⁾		2,680	D	\$26.0)91 ⁽²⁾	42	,464		D			
Common Stock 09/19/2			2022				S ⁽¹⁾		120	D	\$26	5.56	42	,344		D				
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																				
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	if any	med on Date, Day/Year)	4. Transa Code (8)			6. Date Exercis Expiration Date (Month/Day/Ye		ite	7. Title and Amount of Securities Underlying Derivative Secur (Instr. 3 and 4)		De Se (Ir	Price of erivative ecurity estr. 5)	9. Number derivative Securities Beneficiall Owned Following Reported Transactio (Instr. 4)	Owi Fori Dire or li (I) (I	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)		
					Code	v	(A)	(D)	Date Exercis	able	Expiration Date	Title	Amou or Numb of Share	er						
Stock Option (right to	\$2.42	09/19/2022			M			2,800	(3)		12/16/2029	Common Stock	2,80	00	\$0.00	224,72	6	D		

Explanation of Responses:

- 1. The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.
- 2. The price reported is a weighted-average price. The shares were sold at prices ranging from \$25.56 to \$26.55. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
- 3. 1/4 of the shares subject to the option vested on December 1, 2020, and 1/48 of the shares vest monthly thereafter.

Remarks:

Jim Wassil, by /s/ Ron A. Metzger, Attorney-in-Fact

09/21/2022

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.